Original price was: £34.99.£26.99Current price is: £26.99.
-23%for orders over £200
CJC-1295 without DAC, also known as Modified Growth Releasing Factor amino 1-29, usually referred to as Modified GRF (1-29) or “Mod GRF(1-29), is a truncated peptide analogue of growth hormone-releasing hormone (GHRH). CJC-1295 is a naturally occurring growth hormone-releasing factor. As its name implies, CJC-1295 no DAC lacks the ‘drug affinity complex’ described below
CJC-1295 peptide was first developed in the 1980s. Studies with modGRF have shown it to improve muscle repair and growth, accelerate wound healing, enhance strength, increase appetite, strengthen bones, increase fat burning, improve metabolism and improve quality of sleep in animal test subjects. It may also have beneficial effects on blood sugar regulation and the immune system.
CJC-1295 without DAC has been shown to:
Improve muscle repair and growth
Accelerate wound healing
Enhance strength
Increase appetite
Strengthen bones
Increase fat-burning and metabolism
Improve quality
Beneficial effects on blood sugar regulation
Immune system
Anti-ageing
This product is prepared for RESEARCH USE ONLY and may not be used for other purposes.
Research and benefits on CJC-1295 without DAC, also known as, Modified Growth Releasing Factor amino 1-29, usually referred to as Modified GRF (1-29) or “ModGRF(1-29) :
CJC-1295 without DAC, is a synthetic analog of the endogenous peptide signalling hormone Growth Hormone Releasing Hormone (GHRH). Endogenously produced GHRH has 44 amino acids in its chain structure. A truncated synthetic form of GHRH called Sermorelin or GRF 1-29 has 29 amino acids; Modified GRF (1-29) is further changed in that it has four substituted amino in its chain that serve the purposes of preventing degradation and oxidation in manufacture and transport as well as in vivo, while also increasing binding affinity to the GHRH receptors.
What Is DAC?
DAC stands for drug affinity complex. Typically peptides degrade over time, The goal of DAC is to prevent this from happening all while keeping the same biological activity in the peptides. When DAC is added to CJC 1295 it tends to make it degrade at a much slower pace which allows for the body to reap the many benefits of the peptide.
CJC-1295 with or without DAC?
CJC-1295 with DAC does tend to elongate the increase of growth hormone. However, it is less of a natural effect. If you’re looking for more of a natural effect then you’ll want to use the variation that does not have DAC. This variation will create a quick and more natural release of hormones.
The biggest difference between the two is that without DAC the peptide has a much shorter half-life of 30 minutes. This is actually a potentially good thing as it acts more naturally within your body. This means that instead of creating an elongation of growth hormone secretion, your body just gets a quick spurt of growth hormone.
Peptide Structure:
Structure
Synonyms
863288-34-0
CJC-1295
CID 56841945
L-tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide
446036-97-1
Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823.
A Volpe 1, G Coukos, A Barreca, G Giordano, P G Artini, A R Genazzani
Clinical use of growth hormone-releasing factor for induction of superovulation
Affiliations expand
PMID: 1752922 DOI: 10.1093/oxfordjournals.humrep.a137517
Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94.
Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
All articles and product information on this website are for educational purposes only. These products are not medicines or drugs and have not been approved to treat or cure any medical condition.
© 2022 All Rights Reserved
Products shown on this website are prepared for RESEARCH USE ONLY and may not be used for other purposes.
